Results 11 to 20 of about 41,944 (264)

SPHK1 enhances olaparib resistance in ovarian cancer through the NFκB/NRF2/ferroptosis pathway

Cell Death Discovery
PARPis resistance is a challenge in the treatment of ovarian cancer. To investigate the potential mechanism involved in olaparib resistance of ovarian cancer, high-throughput sequencing was performed on olaparib-resistant SKOV3 cell line named SK/Ola ...
Kai Teng, Hanlin Ma, Panpan Gai, Xuelian Zhao, Gonghua Qi   +4 more
doaj   +2 more sources

NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy

Cell Death and Disease
Olaparib has been approved as a therapeutic option for metastatic pancreatic ductal adenocarcinoma patients with BRCA1/2 mutations. However, a significant majority of pancreatic cancer patients have inherent resistance or develop tolerance to olaparib ...
Mingming Xiao, Jing Yang, Mingwei Dong, Xiaoqi Mao, Haoqi Pan, Yalan Lei, Xuhui Tong, Xiaoning Yu, Xianjun Yu, Si Shi   +9 more
doaj   +2 more sources

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

New England Journal of Medicine, 2021
BACKGROUND Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality.
A. Tutt, J. Garber, B. Kaufman, G. Viale, D. Fumagalli, P. Rastogi, R. Gelber, E. de Azambuja, A. Fielding, J. Balmaña, S. Domchek, K. Gelmon, S. Hollingsworth, L. Korde, B. Linderholm, H. Bandos, E. Senkus, J. Suga, Z. Shao, Andrew W. Pippas, Z. Nowecki, T. Huzarski, P. Ganz, P. C. Lucas, N. Baker, S. Loibl, R. McConnell, M. Piccart, R. Schmutzler, G. Steger, J. Costantino, A. Arahmani, N. Wolmark, E. McFadden, V. Karantza, S. Lakhani, G. Yothers, C. Campbell, C. Geyer   +38 more
semanticscholar   +1 more source

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Journal of Clinical Oncology, 2023
PURPOSE Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)–deficient (dMMR) than MMR-proficient (pMMR) disease.
S. Westin, Kathleen N Moore, H. Chon, Jung-Yun Lee, J. Thomes Pepin, M. Sundborg, A. Shai, J. de la Garza, S. Nishio, M. A. Gold, Ke Wang, K. Mcintyre, Todd D. Tillmanns, S. V. Blank, Jihong Liu, Michael McCollum, Fernando Contreras Mejía, T. Nishikawa, K. Pennington, Z. Novak, A. C. de Melo, J. Sehouli, D. Klasa-Mazurkiewicz, Christos Papadimitriou, M. Gil-Martin, Birutė Brasiūnienė, C. Donnelly, Paula Michelle del Rosario, Xiaochun Liu, E. Van Nieuwenhuysen   +29 more
semanticscholar   +1 more source

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

The Lancet Oncology, 2023
BACKGROUND PROpel met its primary endpoint showing statistically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus abiraterone in patients with first-line metastatic castration-resistant ...
F. Saad, N. Clarke, M. Oya, N. Shore, G. Procopio, J. D. Guedes, Cagatay Arslan, N. Mehra, F. Parnis, E. Brown, F. Schlürmann, J. Joung, M. Sugimoto, Oliver Sartor, Yu-Zhen Liu, C. Poehlein, L. Barker, Paula Michelle del Rosario, A. Armstrong   +18 more
semanticscholar   +1 more source

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Journal of Clinical Oncology, 2022
PURPOSE In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients with newly diagnosed advanced ovarian ...
P. DiSilvestro, Susana Banerjee, N. Colombo, G. Scambia, Byoung-Gie Kim, A. Oaknin, M. Friedlander, A. Lisyanskaya, A. Floquet, A. Leary, G. Sonke, C. Gourley, A. Oza, A. González-Martín, C. Aghajanian, W. Bradley, C. Mathews, Joyce F. Liu, J. McNamara, E. Lowe, M. Ah-See, K. Moore   +21 more
semanticscholar   +1 more source

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

New England Journal of Medicine, 2020
BACKGROUND Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with ...
J. D. de Bono, J. Mateo, K. Fizazi, F. Saad, N. Shore, S. Sandhu, K. Chi, O. Sartor, N. Agarwal, D. Olmos, A. Thiery-Vuillemin, P. Twardowski, N. Mehra, C. Goessl, Jinyu Kang, J. Burgents, Wenting Wu, A. Kohlmann, C. Adelman, M. Hussain   +19 more
semanticscholar   +1 more source

Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2 MUT ovarian cancer cells

Scientific Reports, 2023
Olaparib is a PARP inhibitor (PARPi) approved for targeted treatment of ovarian cancer (OC). However, its efficacy is impeded by the inevitable occurrence of resistance.
Łukasz Biegała, Arkadiusz Gajek, Izabela Szymczak-Pajor, Agnieszka Marczak, Agnieszka Śliwińska, Aneta Rogalska   +5 more
doaj   +1 more source

UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors [PDF]

, 2020
Genomic instability can be a hallmark of both human genetic disease and cancer. We identify a deleterious UBQLN4 mutation in families with an autosomal recessive syndrome reminiscent of genome instability disorders.
Beleggia, Filippo, Bustos, Matias A., Checa Rodríguez, Cintia, Goergens, Jonas, Huertas Sánchez, Pablo, Isensee, Jörg, Jachimowicz, Ron D., Velpula, Bhagya Bhavana   +7 more
core   +1 more source

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.

The Lancet Oncology, 2021
BACKGROUND Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum ...
A. Poveda, A. Floquet, J. Ledermann, R. Asher, R. Penson, A. Oza, J. Korach, T. Huzarski, S. Pignata, M. Friedlander, A. Baldoni, T. Park-Simon, K. Tamura, G. Sonke, A. Lisyanskaya, Jae-Hoon Kim, E. A. Filho, T. Milenkova, E. Lowe, P. Rowe, I. Vergote, E. Pujade-Lauraine   +21 more
semanticscholar   +1 more source